[The thromboxane-synthesis inhibitor Ibustrin in the treatment of diabetic angiopathies]

Ter Arkh. 1996;68(10):18-22.
[Article in Russian]

Abstract

16 patients with insulin-dependent diabetes mellitus (IDDM) lasting 8-19 years had pronounced diabetic nephropathy (proteinuria stage), retinopathy (stage I, II or III), disturbed circulation in the lower limbs detected at foot dopplerography. For 3 months these patients received ibustrin (inhibitor of cyclooxigenase, blocker of tromboxane A2 synthesis and platelet aggregation) before renal function underwent positive changes: glomerular filtration rate increased in 13 patients (81%), 24-h proteinuria decreased in 12 patients (75%). Retinal vascular condition improved in 5 of 6 patients with nonproliferative retinopathy and in 2 of 5 patients with preproliferative retinopathy, in 1 and 3 patients stabilization occurred, respectively. In proliferative retinopathy improvement and stabilization were registered in 1 and 3 of 5 patients, respectively. According to feet artery dopplerography the improvement, no changes and moderate aggravation occurred in 10(62%), 3(19%) and 3(19%) of patients, respectively The conclusion is made that ibustrin effectively inhibits progression of IDDM vascular complications, especially at early angiopathy stages.

Publication types

  • English Abstract

MeSH terms

  • Adolescent
  • Adult
  • Blood Coagulation / drug effects
  • Chronic Disease
  • Cyclooxygenase Inhibitors / therapeutic use*
  • Diabetes Mellitus, Type 1 / complications
  • Diabetic Angiopathies / blood
  • Diabetic Angiopathies / drug therapy*
  • Diabetic Angiopathies / physiopathology
  • Diabetic Nephropathies / blood
  • Diabetic Nephropathies / drug therapy
  • Diabetic Nephropathies / physiopathology
  • Diabetic Retinopathy / blood
  • Diabetic Retinopathy / drug therapy
  • Diabetic Retinopathy / physiopathology
  • Drug Evaluation
  • Foot / blood supply
  • Humans
  • Isoindoles
  • Middle Aged
  • Phenylbutyrates / therapeutic use*
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Thromboxane A2 / antagonists & inhibitors*

Substances

  • Cyclooxygenase Inhibitors
  • Isoindoles
  • Phenylbutyrates
  • Platelet Aggregation Inhibitors
  • Thromboxane A2
  • indobufen